Rutin for Health & Longevity

Evidence Review created on 10/09/2026 using AI4L + evidence-mcp / Sonnet 5.5

Also known as: Rutoside, Rutinoside, Quercetin-3-O-rutinoside, Quercetin-3-rutinoside, Sophorin, Vitamin P

Motivation

Rutin (also called rutoside or vitamin P) is a pigment found in buckwheat, citrus fruit, apples, onions and tea. Chemically it is the plant compound quercetin attached to a sugar. It is sold as an oral dietary supplement, typically in 500 mg capsules, and attracts interest as a diet-derived compound that might support health and longevity.

Rutin has a long history. In the 1930s, researchers proposed a vitamin-like role for compounds of this type, and chemically modified relatives are used in parts of Europe for leg-vein complaints. More recently, laboratory studies of aged cells and lifespan studies in flies and mice drew attention, while small human trials have examined blood glucose control and other markers.

This review examines what human trials, animal studies and laboratory data show about rutin and how strong each type of evidence is. It covers possible benefits, risks, interactions with medicines, dosing, product quality and monitoring for adults who actively manage their health and longevity.

Benefits - Risks - Protocol - Conclusion

Three sources with substantial coverage of rutin, one per publication or organization.

No qualifying rutin-specific content was found from Rhonda Patrick, Peter Attia, Andrew Huberman or Chris Kresser (one Kresser podcast mentions rutin only in a list). Fewer than five qualifying sources exist, so the list has three, one Lifespan.io article and two peer-reviewed reviews, and is not padded with marginal content. Life Extension Magazine has no rutin-focused article beyond a promotional skin-formulation piece and a buckwheat article that covers rutin only as one of several compounds.

Grokipedia

Rutin

AI-generated entry on rutin’s chemistry, dietary sources, supplement forms and reported pharmacological properties; fact-checked by Grok rather than peer reviewed.

Examine

Rutin benefits, dosage, and side effects

Examine’s evidence-based entry for rutin, written by Kamal Patel and last updated August 28, 2025, with a linked feed of rutin studies.

ConsumerLab

Quercetin & Rutin Supplements Review & Top Picks

Independent laboratory comparison of ten quercetin and rutin supplements; one rutin product contained 17.4% of its labeled amount. Full results and Top Picks are member-only.

Systematic Reviews

Systematic reviews and meta-analyses on rutin and rutosides (rutin-related compounds), found by a real-time PubMed search.

Of the principal risks, only adverse events of the related phlebotonics are covered by a systematic review (the Cochrane review above); none was found for rutin–drug interactions or the long-term safety of rutin itself.

Mechanism of Action

Rutin is quercetin bound to rutinose (a two-sugar unit), which small-intestine enzymes remove poorly, so absorption depends largely on bacteria in the colon releasing quercetin (Amaretti et al., 2015). In a four-way crossover study (each volunteer tried all four treatments) of 12 volunteers, plasma levels peaked about 7 hours after rutin versus under 1 hour after a quercetin glucoside, with a terminal half-life (time for levels to halve) near 11 hours; only quercetin glucuronides (conjugates the body adds to aid excretion) were detected (Graefe et al., 2001). Metabolism therefore involves bacterial glycosidases (sugar-cleaving enzymes) that release quercetin and, as the glucuronides imply, conjugating enzymes such as UDP-glucuronosyltransferases (enzymes that attach glucuronic acid). Rutin is not selective for one target, and its tissue distribution in humans has not been characterized.

Mechanistic accounts compete. A direct antioxidant role (neutralizing reactive molecules) was not supported by six weeks of 500 mg/day, which raised plasma flavonoids without changing plasma antioxidant status (Boyle et al., 2000). Signalling accounts include dampened inflammatory output from senescent cells (Liu et al., 2024) and inhibition of protein disulfide isomerase (an enzyme supporting clot formation) in laboratory assays and in mice (Jasuja et al., 2012). Rutin also behaves as a hormetin (a compound helpful at low and harmful at high doses), though ideal laboratory concentrations are unreachable in people because of low absorption (Calabrese et al., 2024). Quercetin induced CYP3A (a liver and gut enzyme that breaks down many medicines) in volunteers (Duan et al., 2012).

Historical Context & Evolution

Rutin is named after rue (Ruta graveolens), one of its plant sources (Ganeshpurkar & Saluja, 2017). Its first proposed human use was as a vitamin-like factor: in 1936, Rusznyák and Szent-Györgyi proposed that flavonols (a plant-pigment class including rutin) accompany vitamin C as a second vitamin, “vitamin P” (Rusznyák & Szent-Györgyi, 1936); rutin still carries that alternate name.

Chemically modified relatives, the hydroxyethylrutosides, later became standardized products for chronic venous insufficiency, marketed as Relvène, Venoruton and Paroven; their trials show modest symptom improvement but limited quality (Aziz et al., 2015). A Cochrane review of 69 trials of phlebotonics (a drug class that includes rutosides) found slightly less leg swelling, little difference in quality of life and no clear effect on ulcer healing (Martinez-Zapata et al., 2020).

Interest in health optimization grew from laboratory work: sodium rutin extended mouse lifespan by 10% (Li et al., 2022), fly lifespan rose at moderate and fell at high concentrations (Chattopadhyay et al., 2017), and cultured aged cells released fewer inflammatory signals (Liu et al., 2024). The earliest human data were modest: supplementation raised plasma flavonoids without changing antioxidant status (Boyle et al., 2000), and poor absorption later became a central caveat for the laboratory findings (Calabrese et al., 2024). Human trials of metabolic markers remain few and mixed, so the picture is unsettled in both directions.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no clinical endpoint or validated surrogate has been replicated for rutin itself by independent research groups.

Medium 🟩 🟩

Glycemic control in type 2 diabetes ⚠️ Conflicted

A placebo-controlled trial in 50 adults with type 2 diabetes found lower fasting glucose, insulin, HbA1c (a blood test of average glucose over about 3 months) and insulin resistance (weak response to insulin) with rutin 500 mg/day for 3 months (Bazyar et al., 2023). Rutin with vitamin C showed no HbA1c effect (Ragheb et al., 2020), and 12 weeks in overweight non-diabetic adults changed no glucose or insulin measure (Mathrani et al., 2023). Net reading: one unconfirmed trial; null results used low-dose rutin with vitamin C or non-diabetic adults.

Magnitude: Direction only: fasting glucose, insulin, HbA1c and insulin resistance were lower than with placebo (adjusted p < 0.05 for each, meaning corrected for baseline differences between groups; statistically significant, meaning unlikely to be explained by chance) after 3 months at 500 mg/day; the abstract, the only accessible report, gives no outcome figure or confidence interval (range likely to contain the true value).

Blood lipids in type 2 diabetes ⚠️ Conflicted

The same trial found lower LDL cholesterol (cholesterol carried in low-density lipoprotein particles) and total cholesterol, and higher HDL cholesterol (the high-density counterpart), than placebo (Bazyar et al., 2023). Rutin with vitamin C, at a lower rutin dose (180 mg/day) for 8 weeks, left total cholesterol unchanged (Ragheb et al., 2020). Net reading: lipid improvements rest on one trial and lack confirmation.

Magnitude: Direction only: LDL cholesterol and total cholesterol were lower, and HDL cholesterol higher, than with placebo (adjusted p < 0.05 for each) after 3 months at 500 mg/day; the abstract, the only accessible report, gives no outcome figure or confidence interval.

Blood pressure in type 2 diabetes

A double-blind placebo-controlled trial in 50 adults with type 2 diabetes found lower systolic and diastolic blood pressure and heart rate with rutin (a 1 g tablet containing 500 mg rutin daily for 3 months) than with placebo (Bazyar et al., 2023b). Blood pressure is a validated surrogate (a measurement standing in for clinical outcomes), but the finding rests on one trial from one research group in a diabetes population and is unreplicated.

Magnitude: Change from baseline with rutin versus placebo after 3 months: systolic −8.60 ± 9.32 versus +1.16 ± 5.18 mmHg (p < 0.001) and diastolic −4.20 ± 5.78 versus +0.48 ± 2.40 mmHg (p = 0.001) (mean ± standard deviation, the spread of values; the paper reports no confidence interval, the range likely to contain the true value).

Quality of life in type 2 diabetes

The blood pressure trial also found higher scores for emotional limitations, energy and freshness, mental health and general health with rutin 500 mg/day than with placebo after 3 months on a 36-item quality-of-life questionnaire (Bazyar et al., 2023b). Physical domains did not differ. The finding rests on one trial from one research group in a diabetes population and is unreplicated.

Magnitude: Change from baseline with rutin versus placebo on a 0–100 scale: emotional limitations +27.40 ± 41.69 versus −8.64 ± 26.92 (p = 0.002), energy and freshness +16.00 ± 8.66 versus −1.40 ± 3.95 (p < 0.001), mental health +9.80 ± 8.92 versus −1.12 ± 4.54 (p < 0.001) and general health +18.00 ± 11.65 versus −2.12 ± 9.96 (p < 0.001); unadjusted p values (not corrected for baseline differences), no confidence interval reported.

Low 🟩

Leg swelling and symptoms in chronic venous insufficiency ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Phlebotonics (vein-tone medicines including rutosides) slightly reduced leg swelling, and hydroxyethylrutosides eased pain and heaviness (Martinez-Zapata 2020; Aziz 2015), but rutosides did not beat placebo in post-thrombotic syndrome (Morling 2018). Bears on leg comfort, not longevity; evidence is indirect (rutin relatives). Net reading: modest benefit, not consistent.

Magnitude: Versus placebo, relative risk (RR; events with treatment divided by events with placebo, below 1 meaning fewer) of persistent swelling 0.70 (95% confidence interval, CI, the range likely to contain the true value: 0.63–0.78), ankle circumference −4.27 mm (95% CI −5.61 to −2.93) and quality of life standardized mean difference (SMD; a unit-free effect size) −0.06 (95% CI −0.22 to 0.10) across phlebotonics; for hydroxyethylrutosides, pain SMD −1.07 (95% CI −1.44 to −0.70).

Bleeding from hemorrhoids (multi-flavonoid mixture) ⭕️ Not Central to Health & Longevity

A double-blind multicenter trial of 154 patients compared a mixture of diosmin, troxerutin, rutin, hesperidin and quercetin with a diosmin-based flavonoid comparator; bleeding improved similarly (Corsale et al., 2018). This bears on hemorrhoid symptoms, not longevity. Evidence is indirect: rutin was tested only in a mixture.

Magnitude: Bleeding improved in 79.5% (1 month) and 70.5% (6 months) with the mixture versus 80.2% and 75% with the comparator, without significant differences; satisfaction at 6 months was 4.05 versus 3.25 points (statistically significant).

Intraocular pressure in treated glaucoma ⭕️ Not Central to Health & Longevity

Two studies added a rutin and forskolin supplement to eye drops for glaucoma (optic-nerve damage) and found lower intraocular pressure (pressure inside the eye) (Vetrugno et al., 2012; Pescosolido & Librando, 2010). This bears on eye health, not longevity. Evidence is indirect: rutin was tested only in combination, unblinded.

Magnitude: In 97 patients (52 treated, 45 reference), pressure fell a further 10% (15% when enrollment values were 21 mmHg or higher) while it stayed stable in the reference group; in a 16-patient pilot with no control group (supplement also containing vitamins B1 and B2), the fall was about 20%.

Abdominal visceral fat (monoglucosyl rutin)

An 8-week placebo-controlled trial in 66 healthy Japanese adults tested monoglucosyl rutin, an enzymatically modified water-soluble form, at 200 and 400 mg/day; both authors list one company affiliation, Toyo Sugar Refining, a potential conflict of interest (Hashizume & Tandia, 2020). Evidence is indirect: the compound was modified.

Magnitude: Direction only: visceral fat area fell more than with placebo at both doses after 8 weeks (change from baseline significantly higher than placebo); the abstract, the only accessible report, gives no outcome figure or confidence interval.

Skin elasticity and wrinkles (topical cream) ⭕️ Not Central to Health & Longevity

A double-blind trial in 40 women aged 30–50 applied a rutin-containing cream for 4 weeks and measured skin elasticity and wrinkles against a control cream (Choi et al., 2016). This bears on skin appearance, not longevity. Evidence is indirect: the route was topical, not oral.

Magnitude: At 4 weeks versus the control cream, crow’s feet length was 52.05 mm versus 64.95 mm (improvement 23.90% versus −2.28%) and crow’s feet area 53.15 versus 69.75 mm² (group means; P < 0.05 versus control at the same time point; no confidence interval reported).

Knee osteoarthritis pain (rutoside–enzyme combination) ⭕️ Not Central to Health & Longevity

A double-blind trial in 103 patients with knee osteoarthritis (joint-cartilage wear with pain) compared oral rutoside combined with bromelain and trypsin (protein-digesting enzymes) against diclofenac, an anti-inflammatory medicine, for 6 weeks (Akhtar et al., 2004). This bears on joint pain, not longevity. Evidence is indirect: combination only, no placebo.

Magnitude: The Lequesne Algofunctional Index (a joint pain and function score; lower is better) fell from 13.0 to 9.4 with the combination and from 12.5 to 9.4 with diclofenac; the combination was not inferior to diclofenac (Mann-Whitney estimator, the probability that a patient fares better on the combination, 0.53; lower confidence bound 0.42); no placebo group.

Speculative 🟨

Antioxidant and inflammatory marker shifts ⚠️ Conflicted

Lower inflammatory and oxidation markers in diabetes (Bazyar 2023) contrast with unchanged antioxidant status (Boyle 2000) null results in dialysis (blood-filtering) patients (Omar 2022) and runners (Grabs 2017). Net reading: conflicting; populations and doses differ.

Suppression of inflammatory signalling by senescent cells

In cultured senescent (aged, non-dividing) cells, rutin dampened inflammatory secretions without removing the cells, and it improved chemotherapy response in mice (Liu 2024). No human data exist; the basis is laboratory and animal work.

Lifespan extension in model organisms

Sodium rutin extended mouse lifespan by 10% (Li 2022); rutin extended fly lifespan at moderate concentrations but shortened it at higher ones (Chattopadhyay 2017). No human data exist; the basis is animal only.

Antithrombotic activity

Rutin inhibited protein disulfide isomerase (an enzyme supporting clot formation) and blocked clot formation in mice (Jasuja 2012). No human trial of rutin for clotting was located; the basis is mechanistic.

Liver fat reduction

Sodium rutin reduced liver steatosis (fat accumulation) in aging mice through greater fat oxidation (Li 2022). No human trial has reported results; the basis is animal only.

Cardiovascular protection

A review lists cardioprotective effects of rutin in experimental models (Ganeshpurkar & Saluja 2017). No human trial of rutin on cardiovascular events was located; the basis is animal and laboratory work.

Neuroprotection

Rutin prevented tau (a protein that forms brain tangles) pathology and neuroinflammation (brain inflammation) in a mouse model of Alzheimer’s disease (Sun 2021). No human trial was located; the basis is animal only.

Intestinal inflammation relief ⭕️ Not Central to Health & Longevity

A meta-analysis of nine animal studies found rutin eased experimental inflammatory bowel disease (chronic gut inflammation) (Zou 2025). This bears on gut disease, not longevity. No human data exist; the basis is animal only.

Kidney protection in diabetic animals ⭕️ Not Central to Health & Longevity

A meta-analysis of 13 animal studies found rutin improved kidney function markers in experimental diabetic kidney damage (Li 2026). This bears on kidney disease, not longevity. No human data exist; the basis is animal only.

Benefit-Modifying Factors

  • Gut microbiota (intestinal bacteria): Absorption requires bacterial removal of rutinose, which proved only partial in laboratory tests (Amaretti et al., 2015); high inter-individual microbiota variation and variable responses were observed in a rutin trial (Mathrani et al., 2023).
  • Genetic polymorphisms: No variant has been shown to modify rutin’s benefits; CYP3A5 (a drug-metabolizing enzyme gene) genotype modified quercetin’s enzyme induction (Duan et al., 2012), a possible but untested influence.
  • Baseline biomarkers: Glycemic benefit was reported in adults with type 2 diabetes (Bazyar et al., 2023) but not in overweight adults with normal or prediabetic glucose, whose insulin-producing cell function was largely intact (Mathrani et al., 2023).
  • Sex: Quercetin from oral rutin reached higher levels in women than in men (Erlund et al., 2001); no rutin trial analyzed sex differences in benefit, but quercetin improved vascular function in men and not women with coronary artery disease (Mury et al., 2025).
  • Pre-existing conditions: Venous data come from chronic venous insufficiency, eye data from patients already using eye drops, and metabolic data from type 2 diabetes; benefits outside these groups are untested.
  • Age: No rutin trial stratified by age; venous trials averaged 50 years (Martinez-Zapata et al., 2020), so data for older adults are sparse.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been replicated in controlled human trials of rutin itself by independent research groups.

Medium 🟥 🟥

No risk reaches Medium: the human adverse-event data come from trials of chemically modified relatives or from observational data on a relative, not from controlled rutin trials.

Low 🟥

In 37 placebo-controlled trials of phlebotonics, adverse events were more frequent, gastrointestinal disorders most often (Martinez-Zapata 2020); rutin 500 mg/day caused no adverse blood-chemistry or liver change (Boyle 2000), and rutoside reviews found no serious adverse effect (Aziz 2015). Net reading: mild excess with related compounds; evidence indirect.

Magnitude: Adverse events RR 1.14 (95% CI 1.02–1.27) versus placebo across 37 trials (5,789 participants); gastrointestinal disorders were most frequent. For rutosides in post-thrombotic syndrome, no clear difference from placebo (‘mild side effects’ in 7/41 versus 5/42; Morling et al., 2018).

Altered exposure to co-administered medicines ⚠️ Conflicted

Quercetin, rutin’s metabolite, lowered midazolam and raised pravastatin exposure (total blood level of the drug) in volunteers (Duan 2012; Wu 2012); rutin lowered cyclosporine exposure in rats (Yu 2011). Quercetin left cefprozil exposure unchanged (Jia 2016). Evidence is indirect (human data used quercetin). Net reading: drug-specific, inconsistent effects.

Magnitude: Versus placebo, quercetin 500 mg/day raised pravastatin total blood exposure 24% (95% CI 15–32%) in 16 volunteers and lowered midazolam total exposure from 211.84 to 165.46 ng·h/mL in CYP3A5 variant carriers; cefprozil peak serum concentration was 8.18 µg/mL with versus 8.35 µg/mL without quercetin 500 mg/day in 24 volunteers (no significant difference); rutin lowered cyclosporine total exposure 57.2% in rats.

Congenital anomalies after early-pregnancy exposure (hydroxyethylrutoside)

A Hungarian population-based study comparing affected and unaffected births linked oral hydroxyethylrutoside during the second or third month of pregnancy to ocular coloboma (a gap in an eye structure) and a rare multi-defect syndrome (Pósfai et al., 2014). Evidence is indirect: one observational study of a rutin relative.

Magnitude: Odds ratio (the odds of exposure among affected versus matched unaffected births) 5.4 (95% CI 2.2–12.9) for ocular coloboma and 3.0 (95% CI 1.3–27.4) for the syndrome, which includes ear, digit, genital and anal defects; overall exposure across all congenital abnormalities was lower in cases, odds ratio 0.8 (95% CI 0.7–0.9).

Speculative 🟨

Dose reversal (hormesis) at high exposures

In flies, lifespan rose at moderate rutin concentrations but fell sharply at higher ones (Chattopadhyay 2017); a review notes such biphasic responses are widespread (Calabrese 2024). No human dose-reversal data exist.

Reduced iron availability through chelation

Quercetin binds iron in laboratory settings, a property reviewed in relation to iron metabolism (Xiao 2018). No human study of rutin and iron status was located.

Allergic (hypersensitivity) reactions

A drug-reference monograph lists severe allergic reactions, including breathing problems and swelling of the face or throat, as possible serious side effects (WebMD). No case series were located; the basis is a reference monograph.

Hormone-sensitive cancer and lactation precautions

A drug-reference monograph lists hormone-sensitive cancers (breast, ovarian, uterine) as a condition to discuss before use and notes that quercetin from rutin passes into breast milk (WebMD). No human data were located; basis: monograph.

Added bleeding tendency with clot-preventing medicines

Rutin blocked platelet aggregation and clot formation in cells and mice by inhibiting protein disulfide isomerase (Jasuja 2012). Human bleeding data for rutin were not located; the basis is mechanistic.

Risk-Modifying Factors

  • Genetic polymorphisms: CYP3A5 genotype modified quercetin’s induction of midazolam clearance (Duan et al., 2012); rutin-specific variants affecting adverse events are unknown.
  • Baseline biomarkers: No rutin trial identified a biomarker that predicts adverse events; healthy women showed no adverse blood-chemistry or liver-function change at 500 mg/day (Boyle et al., 2000).
  • Sex: Quercetin had a pro-inflammatory protein signature in women, but not men, with coronary artery disease (Mury et al., 2025), a signal that has not been tested for rutin.
  • Pre-existing conditions: Transplant recipients on cyclosporine face theoretical lowered drug exposure (Yu et al., 2011); users of glucose-lowering or clot-preventing medicines face theoretical additive effects; known rutin or quercetin allergy is a listed reason to avoid use (WebMD).
  • Age: No age-specific rutin safety data exist; venous trials averaged 50 years (Martinez-Zapata et al., 2020), so safety at the older end of the target range is untested.

Key Interactions & Contraindications

  • Cyclosporine and tacrolimus (immunosuppressants, drugs that dampen immune activity): Avoid (theoretical). Rutin and quercetin lowered cyclosporine exposure in rats, risking loss of immunosuppression and transplant rejection; trough level monitoring (blood level just before the next dose) is the mitigation (Yu et al., 2011).
  • CYP3A substrates (midazolam, atorvastatin, simvastatin): Caution (theoretical for rutin). Quercetin 500 mg/day lowered midazolam exposure in volunteers carrying CYP3A5 variants, implying weaker drug effect (Duan et al., 2012); a 1,500 mg/day course showed only a non-significant trend (Nguyen et al., 2015).
  • OATP1B1 (a liver uptake transporter) substrates (pravastatin, rosuvastatin; statins are cholesterol-lowering medicines): Caution (theoretical for rutin). Quercetin raised pravastatin exposure 24% in volunteers, with possible stronger statin adverse effects (Wu et al., 2012).
  • Glucose-lowering medicines (metformin, glipizide, insulin): Monitor (theoretical). Rutin lowered fasting glucose in type 2 diabetes (Bazyar et al., 2023), so additive lowering and hypoglycemia (low blood sugar) are possible; glucose monitoring is the mitigation.
  • P-glycoprotein (a drug-efflux pump) substrates (fexofenadine, talinolol): Caution (theoretical for rutin). Quercetin raised fexofenadine exposure 55% in 12 volunteers (Kim et al., 2009) but lowered talinolol exposure in 18 (Wang et al., 2013), so effects on drug levels are inconsistent; monitor drug response.
  • CYP2E1 substrates (chlorzoxazone; CYP2E1 is a liver enzyme that clears some medicines and alcohol): Caution (theoretical for rutin). Quercetin 500 mg twice daily for 10 days raised chlorzoxazone exposure 69% in 12 volunteers, implying slower clearance of such drugs (Bedada & Neerati, 2018).
  • Cefprozil (antibiotic): No interaction identified. Quercetin 500 mg/day for 15 days left cefprozil peak serum concentration unchanged in 24 volunteers (Jia et al., 2016).
  • Antihypertensive medicines (blood pressure-lowering drugs; amlodipine, lisinopril, losartan): Monitor (theoretical). Rutin lowered blood pressure in a type 2 diabetes trial (Bazyar et al., 2023b), so additive lowering and low blood pressure (hypotension) are possible; blood pressure checks are the mitigation.
  • Anticoagulants (blood thinners) and antiplatelet drugs (drugs that keep platelets from clumping; warfarin, apixaban, clopidogrel): Monitor (theoretical). Rutin blocked clot formation in mice (Jasuja et al., 2012); increased bleeding is possible, and clotting tests (INR, international normalized ratio, for warfarin) are the mitigation.
  • Antivirals (virus-fighting medicines) such as nirmatrelvir with ritonavir: Avoid (theoretical). ConsumerLab reports quercetin might reduce the effectiveness of some antivirals, including a Paxlovid component, with rutin converting to quercetin (ConsumerLab).
  • Chemotherapy (cisplatin, gemcitabine): Caution (theoretical): altered chemotherapy exposure is possible, risking reduced efficacy or added toxicity, though neither has been studied. WebMD states rutin–medicine interactions are not fully understood and flags chemotherapy for discussion with a clinician (WebMD).
  • Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs such as diclofenac, aspirin, ibuprofen): Monitor (theoretical). Rutin raised diclofenac absorption in rats through BCRP (a drug-efflux pump) inhibition (Dogra et al., 2020), so stronger diclofenac effects and side effects are possible; aspirin adds antiplatelet effects, raising bleeding risk.
  • Other flavonoids (quercetin, diosmin, hesperidin): Caution (theoretical). Rutin converts to quercetin, so total quercetin exposure and quercetin-related medicine interactions may add up; mixtures with these compounds have been tested together (Corsale et al., 2018).
  • Glucose-lowering supplements (berberine, chromium): Monitor (theoretical). Additive lowering is possible, given rutin’s effect in type 2 diabetes (Bazyar et al., 2023).
  • Antiplatelet supplements (fish oil, ginkgo, garlic): Caution (theoretical). Additive bleeding tendency is possible, given rutin’s clot-blocking activity in mice (Jasuja et al., 2012).
  • Iron supplements: Monitor (theoretical). Quercetin chelates iron in laboratory settings, which could reduce iron availability (Xiao et al., 2018).
  • Vitamin C: No interaction identified. Rutin with vitamin C has been given together in a diabetes trial without a reported adverse interaction (Ragheb et al., 2020).
  • Alcohol: Caution (theoretical). ConsumerLab reports quercetin may cause headache and facial flushing with alcohol (ConsumerLab); WebMD lists the effect of alcohol on rutin as unknown.
  • Compression stockings: No interaction identified; rutosides performed no better than stockings in post-thrombotic syndrome (Morling et al., 2018).

Populations who should avoid Rutin:

  • People allergic to rutin, quercetin or any ingredient of the specific product (WebMD).
  • Women in early pregnancy (theoretical for rutin): hydroxyethylrutoside exposure in the second or third month was associated with ocular coloboma in one study comparing affected and unaffected births (Pósfai et al., 2014).
  • Transplant recipients taking cyclosporine or tacrolimus (theoretical): rat data show lowered cyclosporine exposure (Yu et al., 2011).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited. No source gives a measured value at which rutin use is to be stopped or reduced, so no stopping threshold is listed.

  • Dose kept within the trial range: Staying at 500 mg/day, the dose used for up to 12 weeks in trials (Mathrani et al., 2023), avoids untested high exposures, mitigating hormetic dose reversal and unknown long-term risk (Calabrese et al., 2024).
  • Taking with a meal: ConsumerLab lists taking rutin with food among the ways to improve absorption and reduce gastrointestinal upset (ConsumerLab), mitigating gastrointestinal adverse events.
  • Medication review before starting: Checking immunosuppressants, statins, midazolam-type sedatives (calming medicines), anticoagulants and antidiabetic medicines mitigates altered drug exposure and additive effects; immunosuppressant trough levels are re-checked within weeks of starting or stopping.
  • Glucose monitoring when on antidiabetic medicines: More frequent fasting glucose checks during the first 3 months mitigate additive glucose lowering and hypoglycemia (theoretical).
  • Clotting monitoring when on warfarin: INR checks after starting mitigate a theoretical added bleeding tendency.
  • Avoiding use in early pregnancy: Not taking rutin or hydroxyethylrutosides around the second and third months of pregnancy mitigates the congenital-anomaly signal seen with a rutin relative (Pósfai et al., 2014).
  • Choosing independently tested products: Third-party testing mitigates unplanned dose variation, which bears on dose reversal and altered medicine exposure, since one rutin product held 17.4% of its labeled amount (ConsumerLab).
  • Avoiding combination products with undisclosed doses: Single-ingredient rutin mitigates added adverse events and medicine interactions from co-ingredients (e.g., forskolin, vitamin C), which mixed-product trials cannot separate from rutin’s own effects.

Therapeutic Protocol

Doses below are cited to trials, product labels or named sources; other parameters without a citation (timing, cycling, titration steps) reflect common practice.

  • Metabolic trial regimens: 500 mg/day for 3 months in type 2 diabetes (Bazyar); 500 mg/day for 12 weeks in overweight adults (Mathrani); 500 mg for 6 weeks in healthy women (Boyle).
  • Retail label dose: One 500 mg capsule daily, per the Life Extension product label (a supplement seller); ConsumerLab notes rutin dosing is less established than quercetin’s typical 500 mg once or twice daily (ConsumerLab).
  • Competing forms: Plain rutin (500 mg/day; Bazyar); monoglucosyl rutin (200 or 400 mg/day, 8 weeks; Hashizume & Tandia); rutin 180 mg/day with vitamin C 480 mg/day (Ragheb; NCT03437902). Doses are not interchangeable; none is the default.
  • Venous regimens (hydroxyethylrutosides): 1 or 2 g/day for 8 weeks (Cesarone et al., 2005) and 1 g twice daily for 3 days around a long-haul flight (Belcaro et al., 2003); these are derivatives, not rutin.
  • Originators: Rusznyák and Szent-Györgyi proposed the vitamin P concept (1936); the Chieti-Pescara vascular group (Cesarone, Belcaro) authored several hydroxyethylrutoside trials (Cesarone et al., 2005).
  • Time of day: No trial tested timing; with a fat-containing meal is common practice, as a high-fat breakfast raised quercetin peak levels 45% in nine adults (Guo et al., 2013).
  • Half-life: Terminal half-life near 11 hours and peak plasma level about 7 hours after oral rutin (Graefe et al., 2001).
  • Single or split dose: The 12-week trial used once-daily dosing (Mathrani et al., 2023); hydroxyethylrutosides were given twice daily (Belcaro et al., 2003); no study compared schedules.
  • Genetic polymorphisms: No pharmacogenetic dosing data exist for rutin; CYP3A5 genotype modified quercetin’s enzyme induction (Duan et al., 2012).
  • Sex differences: Quercetin levels after oral rutin were higher in women than in men (Erlund et al., 2001); no sex-specific rutin dosing exists, and quercetin’s vascular effects differed between men and women (Mury et al., 2025).
  • Age: No age-specific dosing data; the 12-week trial enrolled participants aged 18–65 years (Mathrani et al., 2023), so dosing and response at the older end of the target range are untested.
  • Baseline biomarkers: Glycemic response was reported in type 2 diabetes but not in normal or prediabetic glucose (Bazyar et al., 2023; Mathrani et al., 2023).
  • Pre-existing conditions: Transplant recipients, adults on glucose-lowering or clot-preventing medicines, and pregnancy affect protocol choice (see Key Interactions & Contraindications).

Discontinuation & Cycling

  • Intended duration: Rutin trials lasted 6 weeks to 3 months; hydroxyethylrutosides were studied for up to 8 months (Cesarone et al., 2010). No lifelong-use data exist, and no trial defines short-term versus long-term intent.
  • Withdrawal effects: No withdrawal syndrome was reported in the rutin trials located; the eye-pressure effect of a rutin–forskolin supplement was reversible on stopping (Pescosolido & Librando, 2010).
  • Tapering: No tapering protocol exists, and none was used in the trials located.
  • Cycling: No study tested cycling for rutin; fly data show dose-dependent reversal of benefit (Chattopadhyay et al., 2017), but whether intermittent use matters in humans is unknown.

Sourcing and Quality

  • Label accuracy: ConsumerLab found one rutin supplement with 17.4% of its labeled rutin and another with 88.7% (ConsumerLab); ConsumerLab states it is privately held, with no ownership from or interest in companies selling consumer products.
  • Form and source: One retail 500 mg capsule of pure rutin is extracted from Sophora japonica (Life Extension product label); rutin is 49.5% quercetin by weight (ConsumerLab).
  • Not interchangeable with relatives: Hydroxyethylrutosides, monoglucosyl rutin and water-soluble rutin formulations differ chemically and in absorption; a crossover study by authors affiliated with ALPS Pharmaceutical reported about fivefold higher peak levels for a water-soluble rutin formulation than for quercetin (Yamaguchi et al., 2025).
  • Third-party testing and brands: ConsumerLab tested rutin products from BulkSupplements.com, Country Life, Swanson and Thompson, and named a rutin Top Pick (ConsumerLab).
  • Combination products: Supplements pairing rutin with forskolin, enzymes or vitamin C exist; trial results for these mixtures do not transfer to rutin alone (Vetrugno et al., 2012).
  • Food alternative: Buckwheat tea gave a higher plasma peak than isolated rutin at equal quercetin equivalents, 0.6 versus 0.3 µg/mL (Graefe et al., 2001).

Practical Considerations

  • Time to effect: Leg swelling and symptoms improved within days to 8 weeks with hydroxyethylrutosides in small controlled studies (Cesarone et al., 2005); metabolic effects were assessed at 3 months (Bazyar et al., 2023) and absent at 12 weeks without diabetes (Mathrani et al., 2023).
  • Common pitfalls: Confusing rutin with oxerutins (man-made relatives not studied as rutin) (WebMD); applying quercetin doses to rutin; relying on products with unverified label content (ConsumerLab).
  • Regulatory status: In the United States, the FDA (Food and Drug Administration, the US health regulator) lacks authority to approve dietary supplements before marketing (FDA); a systematic review describes hydroxyethylrutosides as commercially available venous products, e.g., Relvène, Venoruton and Paroven (Aziz et al., 2015).
  • Cost and accessibility: Rutin is sold as a retail supplement (Life Extension product label); ConsumerLab found the cost of 500 mg of quercetin (or potential quercetin from rutin) ranged from 16 cents to over $6 (ConsumerLab).

Interaction with Foundational Habits

  • Sleep: Direction none established. No controlled rutin trial lists sleep as an outcome, and no mechanism for sleep effects has been demonstrated; no timing or technique considerations are supported by data.
  • Nutrition: Direction potentiating (absorption). A high-fat breakfast raised plasma quercetin peak levels 45% and exposure 32% in nine adults (Guo et al., 2013), and buckwheat tea gave higher peaks than isolated rutin (Graefe et al., 2001); gut bacteria release quercetin, so diet shaping the microbiota may matter.
  • Exercise: Direction none shown. Rutoside with digestive enzymes did not attenuate inflammation after a marathon in 138 runners (Grabs et al., 2017); a small cycling-performance trial of rutin was completed in 2025 without posted results (NCT07518355).
  • Stress management: Direction none established. No rutin trial measured cortisol or stress responses; the mechanisms proposed (antioxidant and signalling effects) lack human confirmation on this endpoint.

Monitoring Protocol & Defining Success

Baseline testing depends on the aim: HbA1c and fasting glucose for metabolic aims, a lipid panel for blood lipid aims, blood pressure readings for blood pressure aims or people on antihypertensive medicines, and immunosuppressant levels or clotting tests for people on those medicines. Recording leg symptoms, digestive tolerance and current medicines at baseline provides a reference for later comparison. Ongoing monitoring follows trial durations: metabolic markers rechecked at 3 months, then every 6–12 months, and medicine levels or clotting tests rechecked within weeks of starting or stopping (common practice). Success is judged against the individual’s own baseline, since no rutin-specific target exists, and results are read alongside diet, exercise, sleep and concurrent medicines, which can shift the same markers.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Hemoglobin A1c 4.0–5.6% (standard reference range); no rutin-specific target, so track change from own baseline Marker rutin is expected to change (type 2 diabetes trial) HbA1c (glycated hemoglobin) reflects average glucose over about 3 months; lower than placebo at 3 months in one trial (Bazyar et al., 2023). Glycemic targets in diabetes are clinician-set.
Fasting glucose 70–99 mg/dL (3.9–5.5 mmol/L) (standard reference range); no rutin-specific target, so track change from own baseline Marker rutin is expected to change (type 2 diabetes trial) Fasting for 8–12 hours; no change in adults without diabetes at 12 weeks (Mathrani et al., 2023).
LDL cholesterol, HDL cholesterol and total cholesterol No established target; track change from own baseline Markers rutin is expected to change (type 2 diabetes trial) LDL and HDL are low- and high-density lipoprotein cholesterol; lipid panel; one trial reported improvement, another no total cholesterol change (Ragheb et al., 2020).
Blood pressure No established target; track change from own baseline Marker rutin is expected to change (type 2 diabetes trial); safety check with antihypertensive medicines (theoretical) Seated, rested readings at the same time of day; lower than placebo at 3 months in one trial (Bazyar et al., 2023b).
Immunosuppressant trough level (cyclosporine, tacrolimus) No established target; track change from own baseline Safety check (theoretical): lowered cyclosporine exposure in rats Only for transplant recipients; trough means the sample drawn just before the next dose (Yu et al., 2011).
INR 0.8–1.2 in people not taking anticoagulants (standard reference range) Safety check (theoretical): possible added bleeding tendency Only for people on warfarin; INR (international normalized ratio) is a clotting-time ratio, drawn at the usual anticoagulation clinic times (Jasuja et al., 2012).

Qualitative markers:

  • Leg heaviness and swelling, when used for venous symptoms
  • Digestive tolerability
  • Energy and general well-being

Emerging Research

  • Rutin with vitamin C in fatty liver disease (NCT07310407): Phase 2 (mid-stage trial), 120 participants, not yet recruiting per registry despite a January 2026 start date; primary endpoint: 12-week change in TNF-α (tumor necrosis factor alpha, an inflammatory protein). A positive result would add a disease-population signal; a null result would match the non-diabetic findings.
  • Rutin 500 mg in ulcerative colitis (colon-lining inflammation) (NCT07147842, NCT07370220): Two trials of 60 participants each, without random assignment or full blinding (rutin in active colitis, placebo in remission), completed in 2025, results not posted. Positive results would add human support to animal data (Zou et al., 2025); null results would weaken it.
  • Troxerutin for clotting in COVID-19 (coronavirus disease) (NCT06355258): Phase 1 (early safety trial), 80 participants; the registry still lists recruiting although estimated completion in March 2025 has passed, and no results are posted. A positive result would support clot-related effects of rutin relatives; a null result would weaken them.
  • Rutin with vitamin C in hemodialysis (kidney-replacement blood filtering) (NCT04955145): Phase 3 (large confirmatory trial), 105 participants, registry status unknown, but results are published (Omar et al., 2022): oxidative and inflammatory markers fell in all groups without significant between-group differences; unblinded design; cited in the antioxidant marker item.
  • Completed diabetes trial (NCT03437902): Rutin with vitamin C, 53 participants, completed 2018 and published, with no HbA1c effect (Ragheb et al., 2020); this result is cited in the glycemic control item.
  • Human senescence testing: The senescent-cell findings in cultures and mice (Liu et al., 2024) have no human trial; human senescence-marker data could strengthen or weaken rutin’s longevity relevance.
  • Lifespan replication: The 10% mouse lifespan gain (Li et al., 2022) is unreplicated, and fly data show harm at higher exposures (Chattopadhyay et al., 2017).
  • Absorption-optimized forms: A crossover study by authors affiliated with ALPS Pharmaceutical reported about fivefold higher peak levels for a water-soluble rutin formulation than quercetin (Yamaguchi et al., 2025); clinical outcomes with such forms are untested.
  • Longer metabolic trials: The 12-week non-diabetic trial authors suggest 500 mg and 12 weeks may be insufficient, and benefit may be limited to diabetes (Mathrani et al., 2023).

Conclusion

Rutin is a plant compound, quercetin attached to a sugar, found in buckwheat, citrus fruit and apples and sold as an oral supplement. Most of the human evidence concerns chemically modified relatives used for leg-vein complaints, where leg swelling and symptoms improved modestly and adverse events were slightly more frequent than with placebo. For rutin itself, the strongest human data are a few small trials on blood glucose, blood lipids and blood pressure, with positive and negative results side by side, so even the best-supported benefits rest on single studies and are graded Medium at most in this review. Laboratory and animal findings on signals from aged cells, lifespan in flies and mice, and clot formation remain far from human proof. Absorption is slow and depends on gut bacteria, which may explain why laboratory effects have not carried over cleanly to people. The main risks are mild digestive effects, possible changes in how the body handles certain medicines, and an unresolved signal from a chemically modified relative in early pregnancy; long-term human safety data are limited. Part of the evidence on modified rutin products comes from companies connected to them, and product quality varies, with one tested product containing a fraction of its labeled amount. For health- and longevity-focused adults, the picture is one of plausible but largely unproven benefit, a mostly mild risk profile and considerable uncertainty.

Top - Benefits - Risks - Protocol